Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDA001 in adults following ischemic stroke
NCT01310114Phase 2Terminated
- Sponsor
- Celularity Inc.
- Start
- Mar 2011
- Primary completion
- Mar 2013
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PDA001 in ischemic stroke (3 cohorts), sponsored by Celularity Inc. Primary endpoints: Safety and tolerability of PDA001 at 24 months, Modified Rankin Scale at Day 91 and 1 more. Started Mar 2011; status: terminated.
02
Drugs
PDA001
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT01310114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01310114.